Multimodal Action

Increase in the level of SOD and catalase in serum.
Research suggests that these biomarkers are known for its antioxidant property.

Supporting Joint Tissue Health by reducing the level of MMP3 & MMP7 (a protein that is involved in the metabolism of joint tissue).

Reduction in Cartilage oligomeric matrix protein, glycosaminoglycans, and increase in level of COL2A1.
These biomarkers are known to positively influence cartilage health.

Reduction in COX2, PGE2, C-Reactive protein,& IL10.
These biomarkers are known for general inflammation.

supports joint health by balancing the regular metabolic activities of building and breakdown of the cartilage matrix.

Reducing

Inflammatory mediators
Free radicals

Improving

Anti-inflammatory cytokines
Collagen synthesis gene

Maxicuma^®
In vivo safety

Maxicuma^® was investigated in a single dose and repeated dose acute toxicity studies for 28 days in three different species, in compliance with OECD guidelines and meeting the requirements of 21 CFR (Part 58).

In the absence of any test item-related adverse effects in the above studies, doses up to 220 mg/kg body weight of the rabbits and 440 mg/kg body weight of the Wistar rats, is safe tolerated and is a no-observed-adverse-effect-level (NOAEL) dose. This is equivalent to 4,500 mg/kg body weight/day human dose and hence supports the safe use of Maxicuma^® for the general population.

Cristina Matthewman et al., 2024. Bioavailability and efficacy of ‘free’ curcuminoids from curcumagalactomannoside (CGM) curcumin formulation.

For more details on our advanced ingredients
or technology platforms

Get in touch